Olivier Legrain – joins the board of iia
Olivier Legrain, CEO of the IBA Group, has been appointed as a director of the International Irradiation Association.
Olivier joined IBA SA in 1996 as Controller and was particularly involved in the IPO of the company. In 1998 he was appointed Chief Financial Officer (CFO) of Scanditronix Medical AB Sweden, the new subsidiary of IBA’s dosimetry activities. He returned to the Belgian headquarters for a period of two years before taking the roles of Chairman and Chief Executive Officer (CEO) of Wellhöfer Scanditronix AB from 2001 to 2003 in Sweden. After having successfully managed the dosimetry branch of operations, Olivier Legrain took control of IBA Molecular in 2003 as President. IBA Molecular used to be the radiopharmaceuticals branch of IBA Group. These activities were sold in 2015 in line with the company’s strategy to divest non-core assets in order to focus on proton therapy and associated technologies. In 2011, he became responsible for establishing the future strategy of the IBA Group with his new role as Chief Strategy Officer (CSO).
In May 2012 Olivier became CEO of the IBA Group.